Characteristics and outcomes of COVID-19 patients presumed to be treated with sotrovimab in NHS hospitals in England.

Vishal PatelBethany LevickStephen BoultDaniel C Gibbons Myriam DrysdaleEmily J LloydMoushmi SinghHelen J Birch

Published in: BMC infectious diseases (2024)

Levels of COVID-19-attributable hospitalizations and deaths were low in mAb-treated patients and among subgroups. Similar hospitalization rates were observed whilst Omicron BA.1, BA.2, and BA.5 were predominant, despite reported reductions in in vitro neutralization activity of sotrovimab against BA.2 and BA.5.

Keyphrases

sars cov
newly diagnosed
end stage renal disease
ejection fraction
coronavirus disease
healthcare
chronic kidney disease
peritoneal dialysis
prognostic factors
patient safety
type diabetes